Sexually Transmitted Diseases

The federal agency has given the nod to doravirine/islatravir (Idvynso), a once-daily, 2-drug HIV treatment that demonstrated noninferior efficacy to standard 3-drug regimens in phase 3 trials, expanding options for adults with virological suppression.

New research shows that antiretroviral therapy can reduce HIV-related accelerated biological aging by nearly 4 years, highlighting the critical importance of early and sustained treatment.

TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, offers some insights on the disease burden, and an overview of his company’s pipeline around developing a therapy for this STI.

A new bipartisan bill aims to eliminate cost barriers and expand access to PrEP by mandating comprehensive coverage and launching a national program for uninsured populations.

By launching during the Super Bowl pregame and the Grammy Awards, Gilead’s One2PrEP campaign used music, mainstream media, and bold visibility to normalize conversations about HIV prevention and expand awareness of evolving PrEP options.

In the final FY2026 spending bill, Congress rejected proposed House Republican cuts of more than $1.7 billion and instead maintained bipartisan funding for HIV prevention and treatment programs, while urging the Trump administration to focus on effective implementation.

The workgroup is examining the vaccine’s schedule including the age it is administered, dosage, and the safety and efficacy of the vaccines.

The partnership is a global collaboration to develop Debio1453, a first-in-class antibiotic targeting multidrug-resistant gonorrhea, aiming to strengthen the fragile antibiotic pipeline and ensure future treatment options.

The twice-yearly injectable, which significantly reduces HIV incidence compared with oral regimens, has high adherence and manageable adverse effects.

Amy Colson, MD, MPH, discusses phase 2 data showing durable virologic suppression, low resistance risk, and favorable safety with weekly oral islatravir plus lenacapavir in suppressed adults with HIV.

Zandraetta Tims-Cook, MD, MPH, AAHIVS, discusses access challenges, missed-dose management, and scalable care models for cabotegravir PrEP in women.

Gilead Sciences reported positive phase 3 ARTISTRY-2 results demonstrating that a once-daily single-tablet combination of bictegravir and lenacapavir is statistically noninferior to bictegravir/emtricitabine/tenofovir alafenamide tablets in virologically suppressed adults with HIV. The company plans to file for regulatory submissions for approval.

The antibiotic's approval was based from phase 3 results demonstrating noninferiority to a combination therapy.

GSK’s David Payne, PhD, provides more information are the data from the EAGLE-1 trial.

WHO and UNAIDS warn of service disruptions, widening inequities, and mounting drug-resistance threats, while highlighting innovations and commitments needed to end AIDS as a public health threat.

A DOXYVAC substudy found higher rates of tetM-mediated tetracycline resistance and more isolates with decreased cefixime susceptibility among MSM using doxycycline PEP.

David Cameron, PhD, discusses how researchers discovered its antibiotic, Debio 1453, through structure-guided design and advanced it from potent preclinical activity to first-in-human testing.

Sustained HIV/syphilis elimination of mother-to-child transmission (EMTCT) since 2019 and new hepatitis B validation reflect high antenatal screening, >95% HBV birth-dose coverage, and integrated maternal–child health services.

This newly approved long-acting injectable PrEP offers 6 months of HIV protection, and represents a major scientific and policy breakthrough. However, its success will depend on ensuring equitable access, enforcing coverage requirements, and maintaining a robust, multi-faceted HIV prevention infrastructure amid political and systemic challenges.

Eloise Williams, MBBS, BMedSci, MPHTM, FRACP, FRCPA, details how an 8-criterion genomics-plus-clinical framework narrowed 5,881 isolates to 5 strains while prioritizing safety and contemporary relevance.

Up to 2 million people in low- and lower-middle-income countries may gain access to the long-acting PrEP option under a three-year, no-profit agreement.

WHO and HRP highlight new research on HIV communication, STI priorities, and inclusive strategies to strengthen sexual health worldwide.

This review highlights how people living with HIV are living longer due to antiretroviral therapy but face unique age-related health challenges, including cardiovascular disease, metabolic syndrome, renal dysfunction, neurocognitive decline, immunosenescence, bone loss, and frailty, requiring tailored screening and management strategies.

If this GSK antibiotic is approved, it will provide a new oral option to patients in the US who are currently relying on injectable treatments.

Gilead Sciences has partnered with the Global Fund to supply up to 2 million doses of its long-acting HIV prevention drug, lenacapavir, to low and lower-middle income countries.